TLC BioSciences

30/04/2026

🦴 Big news from OARSI 2026 — TLC599 may do more than relieve pain.

At the OARSI 2026 World Congress on Osteoarthritis, TLC BioSciences shared exciting Phase 3 data showing that TLC599 may also slow the structural progression of knee osteoarthritis — not just reduce pain.

Patients treated with TLC599 showed approximately half the joint deterioration of those on placebo over one year. Combined with its proven 52-week pain relief, TLC599 is now emerging as a candidate for disease-modifying status — something no osteoarthritis drug has ever achieved.

For the hundreds of millions of people living with osteoarthritis worldwide, this could be a turning point. 💙

📄 Read more & access the full poster in the Pressroom at www.tlcbio.com

https://tlcbio.com/en/news/detail/OARSI2026PosterDetails

🦴 OARSI 2026 重大消息——TLC599 不只止痛，還能保護關節！
TLC BioSciences 於 OARSI 2026 世界骨關節炎大會發表 TLC599 的最新第三期臨床試驗探索性分析數據：患者關節退化速度明顯放緩，軟骨磨損幅度僅約為安慰劑組的一半。
搭配已驗證的 52 週顯著止痛效果，TLC599 展現出同時「止痛 + 保護關節」的雙重潛力，朝向全球至今仍是空白的「疾病修飾型骨關節炎藥物（DMOAD）」目標邁進。
對全球數億名受骨關節炎所苦的患者而言，這或許是改變未來治療格局的重要一步。💙

24/04/2026

As OARSI 2026 continues, conversations in osteoarthritis research are increasingly moving beyond symptom relief — toward how we define and measure long‑term joint health.

It’s an important moment for the field, and we’re pleased to be part of the scientific dialogue this week.

14/04/2026

TLC was mentioned by Next Apple News among the Taiwanese companies participating in QIC CEO Week in Singapore.
壹蘋新聞網 提及 TLC 參與於新加坡舉行的 QIC CEO Week，與多家台灣企業共同出席。

https://news.nextapple.com/finance/20260413/E1528EC364DDF7D1ED5AED193898C45A

14/04/2026

Glad to see TLC featured by Yahoo Finance Taiwan highlighting our participation at OARSI 2026 and ongoing scientific exchange in osteoarthritis research.

很高興看到 Yahoo 股市 報導 TLC 參與 OARSI 2026，分享我們在膝骨關節炎研究上的最新科學交流成果。

【財訊快報／記者何美如報導】台灣創新生技公司TLC BioSciences Corp.(以下簡稱TLC)13日正式宣布，旗下研發新藥TLC599的最新臨床數據，以「late-breaking(最新突破性)」摘要之姿，榮獲全球權威的世界骨關節炎大會(OARSI 2026 World Congress).....

13/04/2026

TLC BioSciences to Present Late-Breaking Poster at OARSI 2026

TLC BioSciences will present a late-breaking poster at the OARSI 2026 World Congress, highlighting new Phase 3 exploratory analysis of TLC599.

The data suggest TLC599 may offer potential structural benefit in knee osteoarthritis, supporting its development toward a disease‑modifying therapy.
🔹 Late-Breaking Poster | OARSI 2026 World Congress
🔹 Program: TLC599 (knee osteoarthritis)

🔗 Read the full press release:
https://tlcbio.com/en/news/detail/OARSI2026

07/04/2026

Pipeline Spotlight: Genosphere™ Precision tLNP In Vivo CAR‑T

Built on TLC’s Genosphere™ technology platform, the Genosphere™ Precision tLNP In Vivo CAR‑T program leverages AI‑designed, targeted lipid nanoparticles to enable non‑viral, in vivo CAR‑T delivery. The approach is designed for CD8‑selective targeting and transient, re‑dosable CAR expression, offering a controllable alternative to permanent genetic modification.

This program highlights how the Genosphere™ platform translates advanced delivery science into pipeline‑ready therapeutic candidates, with current applications advancing in B‑cell–driven autoimmune diseases.

25/03/2026

Pipeline Spotlight: TLC518

TLC518 is our long‑acting injectable GLP‑1 designed to support obesity treatment with once‑monthly dosing. Enabled by TLC’s proprietary BioSeizer® sustained‑release platform, TLC518 is engineered to deliver a smooth, steady exposure profile, with the goal of improving convenience, persistence, and real‑world use.

Beyond the product itself, TLC518 highlights the scalability and manufacturing readiness of our long‑acting formulation platforms—supporting the development of sustained therapies across large, chronic disease markets.

17/03/2026

Innovation: Genosphere™ Platform

Genosphere™ is TLC’s next‑generation targeted LNP platform designed to enable non‑viral, in vivo gene delivery. Built for precision, control, and flexibility, Genosphere™ supports CD8‑selective applications, transient mRNA expression, and a re‑dosable in vivo CAR‑T approach for autoimmune diseases.

With a scalable and adaptable architecture, the platform is advancing programs focused on B‑cell–driven autoimmune disorders, offering a new path toward controllable, non‑permanent immune modulation.

10/03/2026

Product Education: Ampholipad™

Ampholipad™ is a complex generic Liposomal Amphotericin B product built using TLC’s proven NanoX® technology. With approvals and partnerships established across several regions—and more in progress—Ampholipad™ showcases TLC’s proven capability in developing and manufacturing high‑quality complex generics.

As we continue to expand availability through additional partnerships, Ampholipad™ stands as a strong example of how TLC translates technical expertise into reliable, globally scalable solutions.

03/03/2026

Innovation Spotlight: NanoX® Platform

Our NanoX® Platform leverages advanced nanoparticle engineering to deliver precise control over delivery, targeting, and release, supporting a new generation of scalable, modular therapeutics. With small single‑layered LNPs and efficient drug loading, NanoX offers true plug‑and‑play adaptability across multiple modalities.

Built for scalability, designed for flexibility, and engineered for performance—NanoX® reflects TLC’s commitment to next‑gen delivery technologies that enable smarter, more efficient therapeutics.

🔎 Learn more about our NanoX® platform and pipeline innovations:
https://www.tlcbio.com/en/technology/NanoX

24/02/2026

Pipeline Spotlight: TLC599

TLC599 continues to advance as a differentiated late‑phase therapeutic candidate for osteoarthritis pain. Clinical data reinforce its potential to deliver up to 24 weeks of sustained pain relief, supported by a safety and efficacy profile aligned with regulatory‑grade expectations.

As we work to address the significant unmet needs in OA pain management, TLC599 reflects our commitment to developing long‑acting, non‑opioid solutions backed by rigorous science and disciplined clinical development.

🔎 Explore our publications TLC599:
https://www.tlcbio.com/en/publications/TLC599